1h Free Analyst Time
Global Chronic Renal Failure Therapeutics Market: About this market
Speak directly to the analyst to clarify any post sales queries you may have.
Chronic renal failure is a general term for a set of heterogeneous disorders that affect the structure and function of the kidney. The chronic renal failure therapeutics market analysis considers sales of antihypertensive therapeutics, antianemia therapeutics, and others. Our analysis also considers the sales of chronic renal failure therapeutics in Asia, Europe, North America, and ROW. In 2018, the antihypertensive therapeutics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the inclusion of antihypertensive therapeutics into various reimbursement schemes will play a significant role in the antihypertensive therapeutics segment to maintain its market position. Also, our global chronic renal failure therapeutics market report looks at factors such as the rising prevalence of chronic renal failure, a strong pipeline and recent approvals, and initiatives from government agencies. However, high genericization of the market, lack of disease-modifying agents, and late diagnosis of polypharmacy may hamper the growth of the chronic renal failure therapeutics industry over the forecast period.
Global Chronic Renal Failure Therapeutics Market: Overview
Rising prevalence of chronic renal failure
The rise in the number of people suffering from cardiovascular and metabolic disorders can result in an increased prevalence of chronic renal failure. There is a high concentration of patients with chronic renal failure from the US, Europe, and Asia. This will boost the need for chronic renal failure therapeutics in these countries and lead to the expansion of the global chronic renal failure therapeutics market at a CAGR of almost 5% during the forecast period.
Development of novel hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors
It has been observed that the oral administration of HIF-PH drugs is ideal for patients. Also, oral HIF-PH inhibitors exhibit minimal side-effects in comparison to other therapeutics. The penetration of these drugs across healthcare centers of various countries is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global chronic renal failure therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic renal failure therapeutics manufacturers, that include Amgen Inc., AstraZeneca Plc, Bayer AG, F. Hoffmann-La Roche Ltd., and Pfizer Inc.
Also, the chronic renal failure therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Table of Contents
PART 01: EXECUTIVE SUMMARYPART 07: CUSTOMER LANDSCAPEPART 09: DECISION FRAMEWORK
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY PRODUCT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
List of Exhibits
Executive Summary
The following companies are recognised as the key players in the global chronic renal failure therapeutics market: Amgen Inc., AstraZeneca Plc, Bayer AG, F. Hoffmann-La Roche Ltd., and Pfizer Inc.Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of novel hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors.”
According to the report, one of the major drivers for this market is the rising prevalence of chronic renal failure.
Further, the report states that one of the major factors hindering the growth of this market is the lack of disease-modifying agents.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned
A selection of companies mentioned in this report includes:
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Pfizer Inc.